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Abstract
The epidemiology of Clostridium difficile infection (CDI) has changed over time and between countries. It is therefore essential to monitor
the characteristics of patients at risk of infection and the circulating strains to recognize local and global trends, and improve patient
management. From December 2011 to May 2012 we conducted a prospective, observational epidemiological study of patients with
laboratory-confirmed CDI at two tertiary teaching hospitals in Perth, Western Australia to determine CDI incidence and risk factors in an
Australian setting. The incidence of CDI varied from 5.2 to 8.1 cases/10 000 occupied bed days (OBDs) at one hospital and from 3.9 to
16.3/10 000 OBDs at the second hospital. In total, 80 patients with laboratory-confirmed CDI met eligibility criteria and consented to be in
the study. More than half (53.8%) had hospital-onset disease, 28.8% had community-onset and healthcare facility-associated disease and 7.5%
were community-associated infections according to the definitions used. Severe CDI was observed in 40.0% of these cases but the 30-day
mortality rate for all cases was only 2.5%. Besides a shorter length of stay among cases of community-onset CDI, no characteristics were
identified that were significantly associated with community-onset or severe CDI. From 70 isolates, 34 different ribotypes were identified.
The predominant ribotypes were 014 (24.3%), 020 (5.7%), 056 (5.7%) and 070 (5.7%). Whereas this study suggests that the characteristics
of CDI cases in Australia are not markedly different from those in other developed countries, the increase in CDI rate observed emphasizes
the importance of surveillance.
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Introduction
Clostridium difficile is an important nosocomial pathogen and the
most frequently diagnosed cause of infectious hospital-acquired
diarrhoea. Clostridium difficile infection (CDI) has a wide clinical
spectrum, varying from asymptomatic carriage, to mild diar-
rhoea, to pseudomembranous colitis [1]. Clostridium difficile
produces two main toxins, toxin A and toxin B, which belong to
the large clostridial toxin family. The genes for toxins A and B,
tcdA and tcdB, respectively, are located on the chromosome in a
19.6-kb pathogenicity locus togetherwith three accessory genes
[2]. Some strains also produce an actin-specific ADP-ribosyl-
transferase known as binary toxin (CDT) [3], the importance of
which is still not clear. Althoughmost clinically important strains
produce both toxins, toxin A-negative, toxin B-positive (A B+)
strains have been widely reported [4]. In recent years, an
increase in the frequency and severity of CDI has been
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associated with the emergence of a binary toxin-producing
strain of C. difficile NAP1/027 (North American PFGE type 1,
UK PCR ribotype 027) [5]. This fluoroquinolone-resistant strain
has been linked to epidemics in North America and Europe.
Major risk factors for clinically apparent CDI include
antimicrobial therapy, hospitalization, residence in a long-term
care facility, older age (≥65 years), and increased length of
hospital stay [1]. Little is known about the epidemiology of
CDI in Australia. Given this lack of information, we undertook
a study of CDI in two large teaching hospitals in Perth,
Western Australia. The primary objectives were to estimate
the incidence of CDI cases for hospitalized adult patients and
to describe the profile of patients with the laboratory-con-
firmed infection. The prevalence of circulating ribotypes was
also determined to understand the molecular epidemiology of
CDI in Western Australia.
Materials and Methods
Setting and study design
This was a prospective, observational, epidemiological study
conducted at the Sir Charles Gairdner Hospital (SCGH), a
600-bed tertiary teaching hospital, and the Royal Perth
Hospital (RPH), an 855-bed tertiary teaching hospital, both
located in Perth, Western Australia. Stool samples sent to the
laboratory for C. difficile testing were monitored from Decem-
ber 2011 to May 2012. All adult patients who submitted loose
stool samples for C. difficile testing over this period were
considered for the study. A minimum target of 35 patients with
laboratory-confirmed CDI per Western Australian hospital
was set. The study was approved by the Sir Charles Gairdner
Group (SCGG) and RPH Human Research Ethics Committees
(SCGG Ref. 2011-133 and RPH Ref. RA-11/036). In Western
Australia, next-of-kin/guardian/carer consent on behalf of the
patient is not acceptable so patients who could not provide
consent were not approached about the study.
Definitions and collection of data
Recently recommended definitions were applied in this study
[6,7]. Patients were classified as having ‘laboratory-confirmed
CDI’ if they experienced the passage of three or more
unformed or loose stools conforming to the shape of a
container (diarrhoea) within a 24-h period and had a C. diffi-
cile-positive laboratory test result. The laboratory testing
method was Becton Dickinson GeneOhmTM, which detects the
toxin B gene (BD, Franklin Lakes, NJ, USA). Specimens from
SCGH patients were screened using a glutamate dehydroge-
nase immunoassay (C. DIFF CHEKTM-60; Alere, Sinnamon Park,
Qld, Australia) before GeneOhm analysis. All specimens that
were glutamate dehydrogenase-negative were regarded as
negative for C. difficile. The consenting patient’s hospital record
was reviewed to confirm the CDI episode. Other data
regarding patient location at onset, risk factors and outcomes
were abstracted from the medical record and by interviewing
the patient using a standardized questionnaire. The number of
occupied bed days (OBDs) was extracted from the respective
hospital administrative databases. Patients fulfilling the case
definition of a laboratory-confirmed CDI were further classi-
fied as having: (1) ‘community-onset CDI’ (when they expe-
rienced diarrhoea in the community or 48 h or less after
admission to the hospital) or ‘hospital-onset CDI’ (when the
onset of diarrhoea was more than 48 h after admission to a
hospital); and (2) ‘healthcare facility (HCF) -associated CDI’
(when they had been discharged from a healthcare facility
within the previous 4 weeks from the onset of CDI symp-
toms), ‘community-associated CDI’ (when they had not been
discharged from a healthcare facility within the previous
12 weeks from the onset of CDI symptoms) or ‘indeterminate
CDI’ (when they had been discharged from a healthcare facility
within the previous 4–12 weeks from the onset of CDI
symptoms). Severe CDI in a patient was defined as one or
more of the following: leucocytosis with a white blood cell
count of >15 000 cells/lL, a serum creatinine level >1.5 times
the pre-morbid level (or if the pre-morbid level was unknown,
1.5 times above the normal range), evidence of severe colitis
(abdominal or radiological signs), temperature >38.5°C,
admission to an intensive care unit for complications associ-
ated with CDI, surgery (e.g. colectomy) for treatment of toxic
megacolon, perforation or refractory colitis due to CDI, death
within 30 days due to or related to CDI.
Clostridium difficile culture and ribotyping
The presence of viable C. difficile was confirmed by culture.
Direct culture of the specimen was performed on CCFA
(cycloserine-cefoxitin-fructose agar containing 0.1% taurocho-
late; PathWest Laboratory Medicine Excel Media [8]). Broth
enrichment in Robertson’s cooked meat medium containing
5 mg/L of gentamicin, 250 mg/L of cycloserine and 8 mg/L of
cefoxitin was performed concurrently and an ethanol-shocked
aliquot was subcultured on CCFA [9,10]. The identity of
putative C. difficile colonies was confirmed by morphology,
odour and chartreuse fluorescence on blood agar, and
L-proline aminopeptidase DIATABSTM (Rosco Diagnostica,
Taastrup, Denmark) reaction.
The PCR ribotyping was performed as previously
described [11]; PCR ribotyping reaction products were
concentrated using the Qiagen MinElute PCR Purification
kit (QIAGEN, Venlo, Limburg, the Netherlands) and resolved
on the QIAxcel capillary electrophoresis platform (QIAGEN).
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Cluster analysis of PCR ribotyping band profiles was performed
using the Dice similarity coefficient with relationships repre-
sented in a UPGMA dendrogram within BIONUMERICSTM software
package v.6.5 (Applied Maths, Saint-Martens-Latem, Belgium).
Ribotypes were identified by comparison of the band profiles
with our reference library, which consisted of a collection of 50
UK ribotypes that included 15 reference strains from the
European Centre for Disease Prevention and Control and the
most prevalent PCR ribotypes currently circulating in Australia
(B. Elliott, T. V. Riley et al., unpublished data). Isolates that could
not be identified with the available reference library were
designated with internal (QX) nomenclature.
Statistical methods
GRAPHPAD INSTAT V3.06 was used to calculate prevalence ratios
and their 95% confidence intervals, and to perform Fisher’s
exact and chi-square analyses. A value of p ≤0.05 was
considered statistically significant.
Results
A total of 2170 specimens from RPH and 2248 specimens from
SCGH were tested for C. difficile over the study period
(Fig. 1). At RPH, the proportion of tests that were
PCR-positive varied from a low of 6.3% in March to a high
of 9.0% in May, with an average of 8.1% positive. At SCGH, the
proportion of PCR-positive tests varied from a high of 13.6% in
February to a low of 7.1% in April, with an average of 10.1%
positive. The difference in proportion of tests positive
between RPH and SCGH was statistically significant in
February 2012 (chi-squared p <0.0389).
The incidence of CDI was estimated from the number of
new patients with C. difficile testing requested who had stool
specimens that were positive for C. difficile. At RPH and
SCGH throughout the study period this reflected the
proportion of specimens tested that were positive for
C. difficile (Fig. 1). There was little variation at RPH during
the nearly 6-month study period with rates varying from 5.2
to 8.1 cases/10 000 OBDs. However, at SCGH, the rates
fluctuated from a low of 3.9/10 000 OBDs in December
2011 to a high of 16.3/10 000 OBDs in January 2012 before
dropping to rates similar to RPH for March, April and May
2012. The average rate at RPH for the study period was
6.8 cases/10 000 OBDs while the average rate at SCGH was
8.0 cases/10 000 OBDs.
From 331 PCR-positive stool specimens from patients at
RPH and SCGH, 80 cases were recruited for further study
(Fig. 2). Initially 154 were excluded because the stools were
not loose or watery (n = 86) or they were repeat samples
from previously PCR-positive patients (68). From the remain-
ing 177 patients for possible inclusion in the study, a total of 88
patients were recruited, with the main reason for exclusion
being inability to consent (58 patients, 32.7%). Of the 88
patients recruited, eight were withdrawn, the main reason
being that they did not meet the definition of CDI (five
patients). Of eligible patients, only six declined to participate in
the study, giving a response rate of 93.6%.
The characteristics of the 80 patients with CDI are shown in
Table 1. The median age of the patients was 60.5 years of age
and just over half (51.3%) were male. Overall, 26.3% of people
with CDI had three or more co-morbidities, with the most
common being: oesophageal reflux (46.3%), hypertension
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FIG. 1. Rates of Clostridium difficile infection (CDI) and proportion of
specimens positive for C. difficile at Royal Perth Hospital and Sir
Charles Gairdner Hospital during the study period, by month. FIG. 2. Recruitment strategy.
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(42.5%), chronic pulmonary disease (36.3%), chronic renal
disease (36%), cancer (35%), immune deficiency (35%) and
rheumatological disease (31.3%). A history of CDI was noted
in 17.5% of patients and 13.8% of patients had undergone a
colonoscopy, sigmoidoscopy or oesophagogastroduodenos-
copy during the admission. The median length of stay for
patients who acquired CDI was 15 days compared with a
median length of stay of 6.0 and 6.1 days for patients at RPH
and SCGH, respectively, during the same period.
Most patients (62.5%) recalled taking antibiotics within the
preceding 3 months (Table 1). The most commonly consumed
antibiotics preceding CDI were amoxicillin / amoxicillin
clavulanate (12.5%) and cephalosporins (11.3%). Just over half
(52.5%) of the CDI patients had consumed antibiotics during
the admission when CDI was diagnosed. The most common
antibiotics received for these patients were: piperacillin
tazobactam (8.8% of patients in the study had previous
exposure), cephalosporins (6.3%), amoxicillin clavulanate
(6.3%) and meropenem (6.3%). Vancomycin, commonly used
in the treatment of CDI, was also implicated in four patients
(5%) before the onset of diarrhoea.
Metronidazole predominated as the treatment of choice for
CDI with 58.8% of patients receiving solely metronidazole and
26.3% receiving both metronidazole and vancomycin (Table 1).
Interestingly, only five patients (6.3%) received vancomycin
alone despite a number of severe cases.
A total of 32 patients (40.0%) in the study had severe CDI
as defined, however, only two patients recruited into the
study (2.5%) died within 30 days. The 90-day crude mortality
rate was 16.3%; six of the 13 deaths were among patients
with severe CDI. A comparison of clinical signs of CDI in
patients with severe versus non-severe disease is given in
Table 2.
Of the 80 CDI cases 55% were readmissions, defined as
having a previous hospital admission for any reason within
the last 4 weeks. The median number of admissions in the
last 3 months was 1 (interquartile range, 0–2.3). More than
half the CDI cases (53.8%) were hospital-onset and 32.6% of
these met the definition of severe CDI. Of the commu-
nity-onset cases (46.3%), 23 (62.2%) were HCF-associated, 6
(16.2%) were community-associated, and 8 (21.6%) were of
indeterminate nature as defined. A comparison between
hospital and community-onset CDI is given in Table 3. There
were no statistically significant differences in risk factors or
outcomes examined other than length of stay where patients
TABLE 1. Characteristics of Clostridium difficile infection
cases
Characteristic
Number of
cases (%) (n = 80)
Age (years)
Median 60.5
Interquartile range 49–71
Male 41 (51.3)
Ethnicity
Caucasian 76 (95.0)
Aboriginal 3 (4.8)
Asian 1 (1.3)
Significant past medical history
Oesophageal reflux 37 (46.3)
Hypertension 34 (42.5)
Chronic pulmonary disease 32 (40.0)
Chronic renal disease 29 (36.3)
Cancer 28 (35.0)
Immune deficiency 28 (35.0)
Rheumatological disease 25 (31.3)
Chronic liver disease 22 (27.5)
Heart disease 19 (23.8)
Gastritis 16 (20.0)
Type 2 diabetes mellitus 13 (16.3)
Colitis 10 (12.5)
Gastric ulcer 8 (10.0)
Connective tissue disorder 8 (10.0)
Irritable bowel disease 8 (10.0)
Diverticulitis 7 (8.8)
Cerebrovascular disease 2 (2.5)
Type 1 diabetes 1 (1.3)
History of CDI 14 (17.5)
Previous antibiotic use in the past 3 months 50 (62.5)
Amoxicillin/amoxicillin clavulanate 10 (12.5)
Cephalosporins 9 (11.3)
Metronidazole 6 (7.5)
Piperacillin tazobactam 5 (6.3)
Vancomycin 4 (5.0)
Clindamycin 4 (5.0)
Trimethoprim sulfamethoxazole 2 (2.5)
Fluoroquinolones 1 (1.3)
Others 27 (33.8)
Duration of previous antibiotic use (days)
Median 14
Interquartile range 8–49
Antibiotic use this admission (before specimen collection) 42 (52.5)
Piperacillin tazobactam 7 (8.8)
Amoxicillin clavulanate 5 (6.3)
Meropenem 5 (6.3)
Vancomycin 4 (5.0)
Fluoroquinolones 4 (5.0)
Ciprofloxacin 3 (3.8)
Moxifloxacin 1 (1.3)
Cephazolin 3 (3.8)
Metronidazole 1 (1.3)
Fluconazole 1 (1.3)
Ceftriaxone 1 (1.3)
Cephalexin 1 (1.3)
Received enteral feeding 1 (1.3)
Underwent OGD/colonoscopy/sigmoidoscopy 11 (13.8)
OGD 7 (8.8)
Colonoscopy 3 (3.8)
Sigmoidoscopy 2 (2.5)
Number of stools in the last 24 h
Median 5.5
Interquartile range 4–10
LOS (days)
Median 15
Interquartile range 7.5–40
CDI, Clostridium difficile infection; OGD, oesophagogastroduodenoscopy; LOS,
length of stay.
TABLE 2. Clinical signs of Clostridium difficile infection
Clinical sign All CDI (%)
Non-severe
CDI (%)
(n = 48)
Severe
CDI (%)
(n = 32)
Prevalence
ratio (95% CI)
Dehydration 53 (66.3) 31 (64.6) 22 (68.8) 1.07 (0.78–1.46)
Hypotension 14 (17.5) 7 (14.6) 7 (21.9) 1.50 (0.58–3.87)
Ileus 2 (2.5) 0 2 (6.3)
Loss of appetite 68 (85.0) 42 (87.5) 26 (81.3) 0.93 (0.76–1.13)
Malaise 49 (61.3) 27 (56.3) 22 (68.8) 1.22 (0.87–1.72)
Megacolon 1 (1.3) 0 1 (3.1)
Nausea 35 (43.8) 18 (37.5) 17 (53.1) 1.42 (0.87–2.31)
Weight loss 48 (60.0) 29 (60.4) 19 (59.4) 0.98 (0.68–1.42)
CDI, Clostridium difficile infection.
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with community-onset CDI stayed for significantly less time
than patients with hospital-onset CDI. Interestingly, severe
CDI was more common among community-onset cases but
this did not reach statistical significance (Fisher’s exact
p 0.173).
Of the 80 cases of laboratory-confirmed CDI, C. difficile was
isolated from 70, 34 at RPH and 36 at SCGH. The ribotypes of
these 70 isolates are shown in Fig. 3. Of the 32 ribotypes
present, the most common was ribotype 014 accounting for
one-quarter (24.3%) of isolates. The next most common were
ribotypes 020, 056 and 070 each at 5.7%, followed by ribotypes
002, 244 and QX 033 (103-like), all at 4.3%. Eighteen (25.7%)
ribotypes were unique, of which 11 could not be assigned a UK
ribotype from our reference collection.
Discussion
Little is known about the epidemiology of CDI in Australia. A
10-year study at SCGH in Western Australia between 1983
and 1992, showed that the incidence of CDI increased from
~3 cases per 10 000 OBDs in 1983 to nearly 7 cases per
10 000 OBDs in 1988 before stabilizing [12]. A significant
decrease in the incidence of CDI at SCGH was observed
10 years later in 1998 when the use of third-generation
cephalosporins was restricted within the hospital, and rates
declined to <2/10 000 OBDs [13]. Recently, routine surveil-
lance of CDI commenced in Victorian public hospitals and a
rate of CDI of 2.2/10 000 OBDs was reported for October
2010 to March 2011 [14]. The rates seen in the current study
were similar to those seen at SCGH in the late 1980s and
exceeded those recently reported in Victoria. The average
rate at RPH for the study period was 6.8 cases/10 000 OBDs
while the average rate at SCGH was 8.0 cases/10 000 OBDs
(Table 1). These rates are similar to those reported for the
Province of Ontario (8.1/10 000 patient days) in Canada in a
study performed from November 2004 until April 2005 but
less than the rates reported for Quebec Province in the same
study (13/10 000 patient days) [15]. It is interesting to note
however that the rate at SCGH in January 2012 (16.3/
10 000 OBDs) exceeded this latter figure. This very high rate
could not be explained by any obvious clustering of cases in
certain wards or by an excess of particular strains, and
requires further investigation. Differences between rates at
RPH and SCGH were also reflected in the higher proportion
of samples that were positive at SCGH (Fig. 1), so may be due
to a difference in thresholds for patient testing. Molton et al.
[16] reported a similar increase in Singapore. CDI rates
increased three-fold, from 4.2 per 10 000 patient days to 12.1
per 10 000 patient days from March 2010 to April 2012.
Community-acquired CDI has been investigated in Western
Australia previously. In a study of diarrhoeal disease with
community acquisition and onset, C. difficile was the second
most commonly detected pathogen after Campylobacter spe-
cies [17]. In the present study, 28.8% of the CDI cases were
community-onset, HCF-associated, 7.5% were commu-
nity-associated and 10.0% were of indeterminate nature as
defined. A similar breakdown of cases was reported from the
Victorian public hospital surveillance system where the same
criteria were used for the time/place of onset of cases [14].
This is likely to be an under-representation of commu-
nity-acquired CDI. The definitions used for this study [6] mean
that any patient who develops CDI within 4 weeks of
discharge from an HCF is classified as having HCF-associated,
community-onset disease, and between 4 and 12 weeks the
TABLE 3. A comparison of hospital-onset and commu-
nity-onset Clostridium difficile infection
Risk factor
Hospital-onset
CDI (%)
(n = 43)
Community-onset
CDI (%)
(n = 37)
Prevalence
ratio (95% CI)
Age ≥65 years 17 (39.5) 15 (40.5) 1.03 (0.6–1.76)
Male 20 (46.5) 21 (56.8) 1.22 (0.8–1.87)
Two or
more chronic
diseases
25 (58.1) 15 (40.5) 0.70 (0.48–1.11)
History of CDI 6 (14.0) 8 (21.6) 1.55 (0.6–4.06)
Severe CDI 14 (32.6) 18 (48.6) 1.49 (0.87–2.57)
Previous antibiotic
use in the past
3 months
25 (58.1) 25 (67.6) 1.16 (0.83–1.63)
Antibiotic use this
admission (before
specimen
collection)
26 (60.5) 16 (43.2) 0.72 (0.46–1.11)
Readmission 21 (48.8) 23 (62.2) 1.27 (0.86–1.89)
LOS ≥20 days 26 (60.5) 8 (21.6) 0.36 (0.19–0.69)
CDI, Clostridium difficile infection; LOS, length of stay.
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FIG. 3. Ribotypes of Clostridium difficile isolated from study partici-
pants at Royal Perth Hospital and Sir Charles Gairdner Hospital during
the study period. Unique ribotypes (*) included 001, 015, 054, 087,
103, 237, 297 and 014/020-group, and local ribotypes QX 001, 013,
024, 050, 081, 097, 103, 113, 161 and 227.
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attribution was indeterminate. However, many of these cases
will be true community-acquired infection given that there is
now good evidence that the rates of community-acquired CDI
around the world are increasing [18,19]. It was noteworthy
that 19% of cases were haematology/oncology patients who,
because of their frequent visits to healthcare facilities, are
always classified as having HCF-associated CDI (data not
shown). However, many of these patients are likely to have
acquired their infection in the community.
In Australia, CDI has been driven by exposure to cepha-
losporins [13]. Not surprisingly, in the present study, previous
exposure to broad-spectrum antibiotics (piperacillin tazobac-
tam, amoxicillin clavulanate, cephalosporins and carbapenems)
was again associated with CDI. This association is similar to
other studies worldwide where cephalosporins as well as
other broad-spectrum antibiotics are the most frequently
implicated antibiotics [13,20,21].
Antibiotic use in the preceding 3 months was the only
significant risk factor identified by Leonard et al. [22] in one of
only two Australian studies assessing risk factors for CDI. In
this small case–control study of diarrhoeal patients at RPH
from 2009–2010, the crude mortality rate (12%) was similar to
the 90-day mortality rate observed in the present study. In
Tasmania in 1997, severe underlying disease, renal impairment,
exposure to antineoplastic agents, and the use of total
parenteral nutrition or nasogastric feeding, all well-known risk
factors for CDI [20], also increased the risk of developing CDI
[23]. The crude mortality rate was 17.2%, and factors
associated with a poor prognosis were older age, severe
underlying disease, renal impairment and failure to treat with
metronidazole or vancomycin. It would appear that little has
changed in Australia in relation to risk factors.
Although over a third of cases were considered severe, the
30-day mortality rate in the present study (2.5%) was low
compared with the 30-day attributable mortalities in studies
from North America: 6.9% overall in Quebec, Canada, during a
ribotype 027 outbreak [24]. This may reflect the lack of
ribotype 027. However, as noted in Fig. 2, a third of patients
assessed were not capable of consenting to inclusion in the
study. In many instances this was because they were too ill and
therefore it is possible that the mortality rate could be higher.
As part of a study that evaluated a new treatment for CDI,
Cheknis et al. [25] typed 24 Australian C. difficile isolates
recovered in the mid-2000s by restriction endonuclease
analysis and found that two-thirds of them were uncommon
types (compared with isolates from North America and
Europe). A quarter of the isolates belonged to restriction
endonuclease analysis group Y, a group that corresponds to
PCR ribotypes 014 and 020. PCR ribotyping is a widely used
and highly discriminatory method for investigating intra-species
variation among C. difficile isolates. In the present study, 32
different ribotypes were identified among 70 isolates from
consecutive patients, emphasizing the diversity of strains in
Australia. Ribotype 014 was again the most commonly
detected at a prevalence of 24.3%. This ribotype seems well
adapted to surviving in the hospital environment as it was
common in the UK before the emergence of the ribotype 027
epidemic strain [11] and is still common in Europe (~10%)
[26,27]. The study by Stubbs et al. [11] from the UK Anaerobe
Reference Unit of 2030 C. difficile strains distinguished 116
types while a study of 330 isolates in a Swedish county
distinguished 53 types [28].
Besides ribotype 014 (which is often grouped with 020 due to
difficulty distinguishing the two), the most prevalent ribotypes in
Europe appear to be 001 (~9%), 078 (~8%), 018 (~6%) and 106
(~5%). A review of ribotyping results across Asia suggested that
017, 018, 014, 002 and 001 were the most prevalent in the
region [29]. In North America, ribotype 027 predominates
(~29%); other common ribotypes include 014 or 020 (~12%),
002 (~5%), 053 (~5%) and 106 (~5%) [30,31]. With such a high
prevalence of 014 and 020 in the present study, other ribotypes
were generally less common than elsewhere with the exception
of ribotypes 056 and 070 (both 6%). Ribotype 056 has been
associated with more complicated infections [27].
Recently, C. difficile ribotype 027 was isolated for the first
time in Australia from a patient who had returned from the USA
[32] and, early in 2010, the first cluster of ribotype 027 cases
was detected in Melbourne, Victoria [33]. Interestingly, C. dif-
ficile ribotype 027 does not appear to have established in
Australia and none was detected in the present study. It is
possible that antibiotic prescribing practices in Australia have
not favoured the emergence of this epidemic strain as the use of
later fluoroquinolones is quite restricted. It is also possible that
the geographic isolation of Australia is also responsible for the
delayed appearance of ribotype 027. However, another poten-
tially epidemic ribotype that produces binary toxin, ribotype
244, was detected at a prevalence of 4.3%. Although this
appears low, it was the equal third most common ribotype
found, and one that was not in Australia 2 years ago. Preliminary
data from other States of Australia, and New Zealand, suggest
that ribotype 244 infection may be associated with more severe
disease [34]. Also of interest, ribotype 237 (A B+ CDT+), a
recently described strain from Australian livestock [35], was
identified in one patient. Ribotype 078, the predominant
livestock strain, which is associated with community-acquired
infection in the northern hemisphere [19], was not seen. This
strain was absent in recent Australian livestock surveys [36,37].
This study has highlighted a significant increase in the rate of
CDI in Western Australia. Surveillance data from other
Australian States suggest that similar increases have occurred
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Australia-wide, and that this may be at least partly due to
community-acquired CDI [38,39]. The contribution of com-
munity-acquired CDI to overall rates may also be masked by
the current definitions used. The emergence of at least one
new virulent strain of C. difficile is a concern, and this needs to
be monitored. Risk factors for acquiring C. difficile in hospital
appear to be unchanged; however, risk factors for community
acquisition require further investigation.
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